Aclaris Therapeutics Inc ACRS

Morningstar Rating
$3.44 −0.06 (1.71%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACRS is trading at a LOCK|TzJQx premium.
Price
$3.50
Fair Value
LOCK|>XYzNB?
Uncertainty
LOCK|?f z&ljR
1-Star Price
LOCK|.GnY&d^
5-Star Price
LOCK|y<P!CTt
Economic Moat
LOCK|Rn
Capital Allocation
—

News

Trading Information

Previous Close Price
$3.50
Day Range
$3.40–3.55
52-Week Range
$2.34–6.60
Bid/Ask
$3.25 / $3.44
Shares Outstanding
158.61M
Market Cap
$545.63M
Volume/Avg
2M / 3M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
73.07
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
73

Valuation

Metric
ACRS
Price/Earnings (Normalized)
—
Price/Book Value
3.11
Price/Sales
73.07
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
ACRS
Quick Ratio
5.09
Current Ratio
5.09
Interest Coverage
—
Quick Ratio
ACRS

Profitability

Metric
ACRS
Return on Assets (Normalized)
−36.39%
Return on Equity (Normalized)
−51.44%
Return on Invested Capital (Normalized)
−56.58%
Return on Assets
ACRS

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|M?lKWTLOCK|?jl@$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|?pg$?gLOCK|LsFp$95B
Moderna Inc
MRNA
LOCK|>fpphgYLOCK|rp>$79B
argenx SE ADR
ARGX
LOCK|FfP$prJLOCK|cRq$59B
BeOne Medicines Ltd ADR
ONC
LOCK|jsW>PW#LOCK|GQ$45B
Royalty Pharma PLC Class A
RPRX
LOCK|DwWfY>@mLOCK|T>#^h$30B
Incyte Corp
INCY
LOCK|?l!&&!%LOCK|>V$23B
BioNTech SE ADR
BNTX
LOCK|vbjD#FLOCK|pr$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|?PWWVTZLOCK|%KFF#$19B
BridgeBio Pharma Inc
BBIO
LOCK|z#CnCb@LOCK|%H$15B

Sponsor Center